Treatment of chronic hepatitis C: can complexity pave the way towards elimination?

Affiliations

¹ UO Gastroenterologia ed Epatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan 20122, Italy.
² UO Gastroenterologia ed Epatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan 20122, Italy. Electronic address: alessio.aghemo@gmail.com.

Comment

Federica Invernizzi et al. Lancet Gastroenterol Hepatol. 2017 Jul.

. 2017 Jul;2(7):465-466.

doi: 10.1016/S2468-1253(17)30085-7. Epub 2017 Apr 14.

¹ UO Gastroenterologia ed Epatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan 20122, Italy.
² UO Gastroenterologia ed Epatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan 20122, Italy. Electronic address: alessio.aghemo@gmail.com.

No abstract available

Comment on

Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
Welzel TM, Asselah T, Dumas EO, Zeuzem S, Shaw D, Hazzan R, Forns X, Pilot-Matias T, Lu W, Cohen DE, Feld JJ. Welzel TM, et al. Lancet Gastroenterol Hepatol. 2017 Jul;2(7):494-500. doi: 10.1016/S2468-1253(17)30071-7. Epub 2017 Apr 14. Lancet Gastroenterol Hepatol. 2017. PMID: 28416221 Clinical Trial.